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SUMMARY – Perioral dermatitis is a common and often chronic dermatosis. In its classic form, 
it primarily affects women aged 15 to 45 years, but there are also variants including lupus-like and 
granulomatous perioral dermatitis, where granulomatous form is more common in childhood and 
affects mostly prepubescent boys. The etiopathogenesis of the disease remains unclear, but there is 
a frequent finding of prolonged use of topical products, especially corticosteroids, in the treatment 
of rosacea and seborrheic dermatitis, preceding the clinical manifestation of perioral dermatitis. 
Other causes important for the occurrence of the disease include various skin irritants, as well as 
other physical and hormonal factors, which all share the epidermal barrier dysfunction as an un-
derlying main pathogenic factor. Clinical presentation of papulovesicular eruption in the perioral 
region with a typical narrow spared zone around the edge of the lips is characteristic. Therapeutic 
approach should be individually addressed, depending on the severity of clinical presentation and 
patient’s age, with special attention to patient’s education and continuous psychological support. In 
mild forms of perioral dermatitis, ‘zero therapy’ is the treatment of choice. In the initial treatment 
period, patients with steroid-induced perioral dermatitis should be closely followed up because the 
rebound phenomenon usually develops after cessation of previous topical treatment. In moderate di-
sease, treatment includes topical metronidazole, erythromycin, and pimecrolimus, whereas in more 
severe cases the best validated choice is oral tetracycline in a subantimicrobial dose until complete 
remission is achieved. Systemic isotretinoin should be considered as a therapeutic option for patients 
refractory to all standard therapies.
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Introduction
Perioral dermatitis is a dermatosis with subacute or 
chronic course, first described in 1957 by Frumess and 
Lewis under the term “light-sensitive seborrhoeid”1. 
It manifests with papules, papulovesicles and papulo-
pustules with a diameter of 1 to 2 millimeters, which 
progressively join to clusters, situated on erythematous 
base. Skin changes typically appear in the perioral re-
gion with a characteristic spared skin zone around the 
edge of lips. Lesions gradually spread to nasolabial 
folds, cheeks and lateral portions of lower lids.
Light-skinned people are primarily affected; pre-
dominantly women aged 15 to 45 years, with a peak 
incidence in the second and third decade of life. Be-
sides, the number of male patients suffering from pe-
rioral dermatitis has also been increasing, presumably 
because of the more common use of cosmetic prod-
ucts among men. Perioral dermatitis may also occur 
in childhood and it affects mostly boys, with the peak 
incidence in the prepubescent period2. 
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Etiopathogenesis
In a large portion of patients with perioral der-
matitis, there is an evident history of previous use 
of topical corticosteroids. On the other hand, it can 
occur without previous topical corticosteroid use (id-
iopathic perioral dermatitis). Some authors suggest 
that perioral dermatitis is a result of facial skin in-
tolerance to repetitive irritation3. It is believed that 
the main pathogenic factor is impaired skin barrier 
function. Additionally, the majority of patients have 
atopic diathesis4. Although the exact etiopathogenesis 
of perioral dermatitis has not yet been fully explained, 
several etiopathologic factors have been proposed.
Topical corticosteroids
The absorption level of topical corticosteroids de-
pends on the potency of corticosteroids, the body area 
(face and neck absorb greater amounts of corticoster-
oids) and the duration of administration5. 
The duration of topical steroid use required to in-
duce perioral dermatitis varies among individuals; by 
own experience, only a few weeks of application of 
even mid-strength or mild topical steroid can result in 
typical perioral dermatitis, whereas in some patients 
it develops after years of topical steroid application. 
The reason for uncritical use of corticosteroids varies 
among patients, but, according to our experience, the 
most common primary dermatoses include seborrheic 
dermatitis and rosacea. During a period of 3 years 
(1999-2001), in our Department we followed 450 pa-
tients with a history of prior use of topical steroids last-
ing from several weeks to even 24 years. The primary 
dermatosis was seborrheic dermatitis in 203 (45.1%), 
rosacea in 158 (35.1%), acne in 44 (9.8%), unrecog-
nized dermatomycosis in 8 (1.8%) patients, and other 
reasons like cosmetic cleansing or after-shave use in 
37 (8.2%) patients. The common scenario includes a 
patient who starts application of a less potent corticos-
teroid with transient improvement of the initial skin 
lesions, but later on it is followed by development of 
full perioral dermatitis manifestation. This often leads 
to further use of high-potent corticosteroids in order 
to alleviate skin symptoms, which only makes clinical 
presentation ever more severe, leading to the vicious 
circle of steroid usage and gradual worsening of the 
disease.
There are several epidermal and dermal changes 
that have been associated with the prolonged use of 
topical steroids. Generally, patients with perioral der-
matitis have an initially impaired epidermal barrier 
function, with topical steroids only aggravating this 
disturbance6. Consequently, transepidermal water 
loss (TEWL) is increased, accompanied by delayed 
response and recovery of permeability barrier. The 
amount of epidermal lipids including ceramides is re-
duced, whereas dermal changes include reduction of 
collagen and elastic fibers. It is believed that topical 
corticosteroids damage the wall of the hair follicle, 
which is followed by edema in the follicle cells, which 
may play the crucial role in the development of granu-
lomatous perioral dermatitis7,8.
Skin irritants
Excessive use of moisturizing creams, especially 
the ones based on petroleum jelly or paraffin, can 
cause follicular occlusion and irritation. As a result, 
epithelial barrier becomes dysfunctional, leading to 
edema of the stratum corneum and increased TEWL9. 
This manifests as a feeling of tension and dryness of 
the skin. Other skin irritants, such as decorative cos-
metics, creams with a high sun protecting factor, or 
even fluorinated toothpaste can lead to the same skin 
disorders and manifestation of perioral dermatitis.
Physical factors
Sunlight and exposure to ultraviolet radiation 
could be a possible cofactor in the development of pe-
rioral dermatitis. On the other hand, some patients 
noted skin changes getting worse during winter and 
prolonged wind exposure.
Hormonal factors
Since the majority of people suffering from perio-
ral dermatitis are women, hormonal changes and the 
use of oral contraceptives are considered to be the pos-
sible etiologic factors. Some women noted worsening 
of skin changes during premenstrual period2. 
Microbiological factors
Although the bond between the microbiological 
factors and perioral dermatitis has not yet been defi-
nitely proven, there have been cases in which certain 
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species, such as Candida albicans, fusiform bacteria 
and Demodex folliculorum mite were isolated from skin 
lesions. 
Clinical Presentation
Classic perioral dermatitis 
Perioral dermatitis typically presents with numer-
ous small, red to red-brown papules, papulovesicles 
and rarely papulopustules, 1 to 2 millimeter in di-
ameter. Lesions are situated on a sharply delimited 
erythematous base and appear mostly in the perioral 
region, with a characteristic spared zone around the 
edge of lips. Skin lesions are often grouped together 
and they can fuse and affect larger areas, appearing 
on the nasolabial folds and lower eyelids. Wider areas 
of the face, such as the glabella, upper eyelids and the 
forehead are rarely affected. 
Diffuse erythematous skin shows signs of discrete 
scaling, whereas the surrounding skin is often dry, 
leading to sensation of tension, slight burning and 
pain in the affected areas. Secondary bacterial in-
fection of the skin lesions or infestation by Demodex 
mites is also possible in patients with chronic perioral 
dermatitis.
Differential diagnosis includes rosacea, seborrheic 
dermatitis, childhood granulomatous perioral der-
matitis, allergic contact dermatitis and ‘lip-licking’ 
cheilitis.
Lupus-like perioral dermatitis 
Lupus-like perioral dermatitis is a clinical vari-
ant of perioral dermatitis. The main difference from 
the classic form is the appearance of dense clusters 
of larger, succulent, red to brown papules and papu-
losquamous lesions in the perioral area. Periorbital 
region can be affected as well. Skin lesions show yel-
lowish discoloration on diascopy and are more prone 
to heal with scars10.
Childhood granulomatous perioral dermatitis
Granulomatous perioral dermatitis is a form of 
perioral dermatitis which is more common in chil-
dren. First described by Gianotti et al. in 197011, it 
was thought to be almost exclusive among Afro-
Caribbean children, which gave its first name, ‘facial 
Afro-Caribbean childhood eruption’. But this clinical 
entity got its current name in 1996, implying that it 
manifests in childhood, regardless of race12,13.
It occurs in children aged 7 months to 14 years, 
mainly in prepubescent period and is more common in 
boys14. Topical steroids (particularly fluorinated corti-
costeroids) are considered as either the main cause or 
as a worsening factor. Clinical presentation includes 
discrete yellow to brown or even reddish papules 1 
to 3 millimeter in diameter, positioned primarily in 
the perioral region. Skin changes can also be found 
in the perinasal and periocular areas, as well as in the 
extrafacial areas, such as limbs or trunk. The course 
of disease is mild and skin lesions heal without scar-
ring and pigmentation disorders. Skin changes regress 
spontaneously after a few months and therefore most 
cases require no therapy.
Differential diagnosis includes several skin condi-
tions such as classic perioral dermatitis, granuloma-
tous rosacea, sarcoidosis, and disseminated miliary 
lupus of the face.
Therapy
The choice of treatment depends on the severity 
of the disease and patient’s compliance. Mild forms 
of perioral dermatitis can be successfully treated with 
topical agents, whereas moderate to severe forms of 
the disease require systemic therapy. 
However, the first therapeutic step should consist 
of complete cessation of all topical products, which is 
called ‘zero therapy’ and it is usually applied during 
the first few weeks of treatment. During this period, 
the application of all topical products, including both 
skin care products and topical medications, should 
be discontinued, particularly topical corticosteroids 
and lipid-rich cosmetics. The patient should also be 
instructed to avoid all skin care products, soaps, as-
tringents and abrasives. According to our experience, 
local application of compresses of normal saline solu-
tion or chamomile tea during the few initial weeks of 
treatment is usually beneficial.
‘Zero therapy’ may be sufficient in the treatment of 
mild forms of perioral dermatitis. On the other hand, 
special attention should be paid to patients with corti-
costeroid-induced perioral dermatitis, who usually de-
velop ‘rebound phenomenon’ after cessation of topical 
steroids, manifested with edema, erythema and papu-
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lopustular eruption with itching and burning. At this 
point, there is a high risk of patient’s non-compliance, 
when some patients continue to apply the same or an-
other topical steroid. However, some authors suggest 
tapering the frequency of topical steroid application 
or prescribing lower potency topical steroid, with the 
aim to mitigate the rebound flare. This approach is not 
consistent with our experience, as we suggest abrupt 
cessation of topical steroids, since ‘tapering’ approach 
commonly leads only to further uncontrolled use of 
steroids and prolongs the treatment. Patients should 
be explained that during the first few weeks, exacer-
bations are expected and that the treatment can take 
a long course in severe cases. Therefore, continuous 
psychological support and encouragement is essential 
for good compliance and therapeutic success.
Topical therapy
Several topical agents have been successfully used 
in the treatment of perioral dermatitis, but no single 
topical medication has shown to be superior to others. 
Topical medications are required when ‘zero therapy’ 
applied for a few weeks produced no appropriate ef-
fect and are usually sufficient in moderate forms of 
the disease. However, some patients complain of ir-
ritation after introducing any topical agent, which is 
most commonly observed in corticosteroid-induced 
perioral dermatitis. In these patients, the period of 
‘zero therapy’ should be prolonged.
Among topical agents, metronidazole is most 
commonly used in the treatment of perioral derma-
titis. It is a synthetic derivative of nitroimidazole 
with antimicrobial, anti-inflammatory and antioxi-
dant properties15,16. A retrospective study performed 
by Nguyen and Eichenfeld included 79 children and 
adolescents with perioral dermatitis17. Treatment with 
metronidazole cream or gel was associated with clear-
ing of the rash, whereas treatment with a calcineurin 
inhibitor, hydrocortisone, sulfacetamide, or an anti-
fungal agent was not effective. The authors conclude 
that topical metronidazole for 1 to 2 months should be 
the first line treatment in children with perioral der-
matitis, with the addition of oral erythromycin if the 
condition persists. On the other hand, in a prospective 
study that included 108 adult patients with perioral 
dermatitis, 1% topical metronidazole was compared 
with oral tetracyclines. Treatment lasted for 8 weeks 
and the results revealed that metronidazole led to re-
duction of the number of papules, but tetracyclines 
obtained better results, leading to complete regres-
sion of the rash15. However, topical metronidazole is 
proven to be a good therapeutic choice in cases when 
tetracyclines are contraindicated or when patients re-
fuse systemic treatment16.
Other topical agents that have been used in the 
treatment of perioral dermatitis include topical eryth-
romycin, azelaic acid, adapalene, and calcineurin in-
hibitors18. Topical erythromycin was compared with 
oral doxycycline and placebo in a study that includ-
ed 99 patients; 33 patients were treated with topical 
erythromycin, 35 patients were treated with perioral 
doxycycline, and 31 patients received placebo. In both 
patient groups, treated with either topical erythro-
mycin or perioral tetracycline, significantly better 
therapeutic effects were observed when compared to 
the group that received placebo. Also, there was no 
difference in the effectiveness between topical eryth-
romycin and perioral doxycycline19. 
Azelaic acid has also been successfully used in pa-
tients with perioral dermatitis20. Its use has been par-
ticularly investigated in children with perioral derma-
titis. Jansen et al. report good therapeutic results with 
20% azelaic acid cream when treated 8 children with 
perioral dermatitis, aged 3 to 12 years. Complete re-
mission was observed within 4 to 8 weeks of cream 
administration21.
Therapeutic effect of pimecrolimus, a topical cal-
cineurin inhibitor, was investigated in a study con-
ducted on 40 patients aged 21 to 69 years; 1% pime-
crolimus cream was administered twice a day for 4 
weeks, with 50% reduction of the severity index after 
2 weeks of treatment22. However, topical calcineurin 
inhibitors should be used with caution, as there are 
reports of induction of rosaceiform dermatitis after 
the use of tacrolimus ointment. The authors have sug-
gested the possible role of various factors in the de-
velopment of this phenomenon, including occlusive 
properties of the ointment, as well as proliferation of 
Demodex due to local immunosuppression and vasoac-
tive properties of tacrolimus23.
Systemic therapy
Systemic treatment is the treatment of choice in 
severe cases of perioral dermatitis and in mild to mod-
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erate forms of the disease if there is no clinical im-
provement after topical therapy.
Oral tetracyclines are systemic treatment of choice 
in patients with perioral dermatitis, except for chil-
dren younger than 8 years, pregnant women, and in 
cases of hypersensitivity to tetracyclines. In this indi-
cation, therapeutic effect of tetracyclines lies in their 
anti-inflammatory activity, including inhibition of 
nitric oxide production, down-regulation of matrix 
metalloproteinase expression, inhibition of serin pro-
tease activity, and reduction in the activity of reactive 
oxygen species. First generation tetracyclines were 
gradually replaced by doxycycline and minocycline. 
Nowadays, doxycycline is favored, given that minocy-
cline may induce autoimmune hepatitis and systemic 
lupus erythematosus-like syndrome. Traditionally, 
doxycycline has been administered in the initial dose 
of 100 to 200 mg daily; the dose is halved after 3 to 4 
weeks and continued to complete regression of clini-
cal symptoms. Treatment period usually took 8 to 10 
weeks. However, the fact that there is no definitive 
evidence that perioral dermatitis is caused by bacte-
ria has led the authors to administer subantimicrobial 
dose of doxycycline (modified release, 40 mg daily). 
Therapeutic effect of this dose on inflammatory lesions 
was equal when compared with doxycycline 100 mg 
daily, with advantages of the subantimicrobial dose in 
the absence of antibiotic resistance and a significantly 
lower risk of gastrointestinal side effects24.
Oral macrolides are a therapeutic option in cases 
when tetracyclines are contraindicated. The macrolide 
of choice is erythromycin, which has shown effective-
ness particularly in treating children with granuloma-
tous perioral dermatitis12. 
Isotretinoin is used in rare cases of perioral derma-
titis that have been refractory to any other therapeutic 
option. Good therapeutic results were obtained in lu-
pus-like perioral dermatitis and in childhood granu-
lomatous perioral dermatitis10,25.
Discussion
Treatment algorithm for perioral dermatitis has 
been proposed and it serves as a general and useful 
guideline3. However, there is no universal therapeutic 
approach applicable to all patients. The choice of treat-
ment primarily depends on the severity of the disease, 
but also on various factors including facial skin toler-
ance, patient’s compliance and the results of previous 
therapy. The initial treatment period is of particular 
importance in patients with steroid-induced perioral 
dermatitis because the rebound phenomenon usually 
develops after cessation of previous topical treatment. 
If the patient is not properly educated, the compli-
ance is poor and the patient usually stops with rec-
ommended treatment and continues with the appli-
cation of even more potent topical steroids. Another 
delicate issue is the choice of time when to stop with 
‘zero therapy’ and introduce topical medication. As 
topical steroids aggravate disruption of the epidermal 
barrier, some patients with steroid-induced perioral 
dermatitis often do not tolerate any topical product 
for several weeks and experience burning sensations 
even after application of neutral creams. Furthermore, 
when choosing the topical treatment option, the risk 
of irritation should be considered, particularly when 
administering topical retinoids and azelaic acid. Both 
exacerbation of the disease in the initial period and 
poor tolerance of topical agent may again influence 
patient compliance. Additionally, some patients with 
mild and moderate disease cannot accept that in some 
cases therapeutic effect of topical treatment can be ob-
served only after several weeks and therefore interrupt 
the treatment. In such cases, earlier introduction of 
systemic therapy should be considered. On the other 
hand, some patients refuse oral tetracyclines and pre-
fer topical treatment even in severe cases.
Further issue that should be carefully considered is 
the duration of treatment with oral tetracyclines. The 
treatment should be continued until complete remis-
sion is achieved, which is usually observed after 8-10 
weeks of treatment. It has been observed that recur-
rences are more likely to develop if the duration of 
systemic treatment is not sufficient26. As there is evi-
dence for increasing development of antibiotic-resis-
tant bacterial strains, long term treatment with doxy-
cycline 100 mg daily should be avoided. The absence 
of the risk of antibiotic resistance and a significantly 
lower risk of gastrointestinal side effects favor the use 
of subantimicrobial dose of doxycycline (modified 
release, 40 mg daily). Finally, there are rare but not 
negligible patients who are refractory to all standard 
therapeutic options. In these patients, treatment with 
low doses of isotretinoin should be considered, with 
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special attention to women of childbearing potential 
because of its teratogenic effect, who then require ad-
equate contraception. 
It is concluded that therapeutic strategy for perio-
ral dermatitis should be adjusted individually, with 
special attention to patient education and continuous 
psychological support.
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Sažetak
PERIORALNI DERMATITIS: JOŠ UVIJEK TERAPIJSKI IZAZOV
Z. Bukvić Mokos, A. Kummer, E. Lazić Mosler, R. Čeović i A. Basta-Juzbašić
Perioralni dermatitis je česta dermatoza, nerijetko kroničnog tijeka, od koje najčešće obolijevaju žene u dobi od 15 do 
45 godina. Uz klasični oblik perioralnog dermatitisa postoje još i lupoidni te granulomatozni oblik bolesti koji se najčešće 
javlja u dječaka u predpubertetskom razdoblju. Etiopatogeneza perioralnog dermatitisa nije u potpunosti razjašnjena, no 
zna se da važnu ulogu ima dugotrajna uporaba lokalnih pripravaka od kojih su najvažniji lokalni kortikosteroidi. Uz to, 
za nastanak bolesti važni su i razni kožni iritansi te drugi fizikalni i hormonski čimbenici koji narušavaju funkciju epi-
dermalne barijere, poremećaj koje je osnovni patogenetski čimbenik perioralnog dermatitisa. Klinička slika je znakovita: 
nalazi se papulovezikulozna erupcija s tipičnom uskom pošteđenom zonom oko ruba usnica, koja je temelj za postavljanje 
dijagnoze bolesti. U terapiji je nužan individualni pristup koji ovisi o težini kliničke slike i dobi bolesnika, s naglaskom 
na podučavanju bolesnika i stalnoj psihološkoj potpori. Takozvana „nulta terapija“ je najbolji pristup u slučaju blažih obli-
ka bolesti, pri čemu u početnom razdoblju liječenja osobitu pozornost zahtijevaju bolesnici s perioralnim dermatitisom 
izazvanim steroidima, s obzirom na to da se u tom razdoblju očekuje pogoršanje znakova i simptoma bolesti uzrokovano 
naglim prestankom primjene dotadašnjih topikalnih pripravaka. Za liječenje umjereno teških oblika bolesti dolaze u obzir 
lokalni metronidazol, eritromicin i pimekrolimus, dok su oralni tetraciklini lijek izbora u težim slučajevima perioralnog 
dermatitisa, a primjenjuju se u subantimikrobnoj dozi do potpunog povlačenja promjena na koži. Sustavno liječenje izotre-
tinoinom je terapijski izbor u bolesnika refraktornih na sve druge standardne oblike liječenja.
Ključne riječi: Dermatitis, perioralni – etiologija; Dermatitis, perioralni – terapija; Individualizirana medicina
